Inflammation and Immunology Areas of Interest

Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.kddsystems.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. A formal notification regarding the status of your application will be sent once a decision is reached. Pfizer support will only be extended upon the execution of a research agreement. For any questions, please send an email to [email protected].

Atopic Dermatitis

Research areas to be considered for Pfizer support include:

  • Basic and clinical research to further characterize the various endotypes and phenotypes of AD and their response to AD treatments
  • Non-interventional studies (including epidemiological studies) to examine comorbidities associated with AD, disease burden, costs and unmet need for new treatments
  • Mechanistic insights into the role of PDE-4 and/or JAK/STAT pathways in AD

Inflammatory and non-inflammatory diseases and conditions with potential benefit from topical application of a PDE-4-inhibitor (Crisaborole)

Research areas to be considered for Pfizer support include:

  • Mechanistic research on the role and effect of PDE-4 or its inhibition in skin diseases and conditions
  • Clinical research of PDE-4-inhibition in inflammatory skin diseases and conditions
  • Real-world applications of crisaborole in AD management

Inflammatory and non-inflammatory diseases and conditions with potential benefit from systemic inhibition of the JAK-1 pathway (Abrocitinib)

Research areas to be considered for Pfizer support include:

  • Mechanistic insights into the role of the JAK/STAT pathway in inflammatory and non-inflammatory skin diseases
  • Clinical research into the use of JAK-1-inhibitors in AD and other inflammatory and non-inflammatory conditions (e.g. dermatologic diseases, including, but not limited to, eczematous disorders, connective tissue diseases, autoimmune blistering disorders, lichenoid eruptions, granulomatous dermatoses, neutrophilic dermatoses, cutaneous vasculitides, alopecia, scarring alopecias, prurigo nodularis, and chronic prurigo of unknown origin.)
  • Optimization of healthcare delivery for patients with moderate-severe AD

Inflammatory and non-inflammatory diseases and conditions with potential benefit from systemic inhibition of the JAK3/TEC pathway (Ritlecitinib)

Research areas to be considered for Pfizer support include:

  • Mechanistic insights into the role of JAK3 and TEC pathways in skin diseases
  • Clinical research into the use of JAK3 and TEC inhibition in skin diseases
  • Unmet need/Burden of Disease/epidemiology of AA and Vitiligo

Inflammatory Conditions

Research areas to be considered for Pfizer support include:

  • Assessment of patients who switch agents during their treatment
  • Prediction of response to treatment 
  • Evaluation of special populations
  • Characterization of the mechanistic basis and durability of monotherapy
  • Non-clinical examination of the relative efficacy/specificity of JAK inhibitors
  • Studies to investigate the mechanistic basis of herpes zoster risk
  • Evaluations of the impact of value-added-services on PROs and adherence
  • Impact of diet on disease

Gastroenterology

Research areas to be considered for Pfizer support include:

  • Evaluation of biomarkers as predictors of efficacy in UC
  • Evaluation of lipid elevations observed in UC patients
  • Evaluation of the ability to restart therapy after interruption in UC patients

Spondyloarthritis (SpA)

Research areas to be considered for Pfizer support include:

  • Studies of unmet medical need/disease burden in SpA/PsA/AS (e.g., early diagnosis tools, oral dosing/patient preference, adherence)
  • Examination of real-world data
  • Efficacy measurements for SpA/PsA/AS clinical research
  • Characterization of how appropriate treatment reduces disease activity in the core domains of psoriatic arthritis with a focus on skin, enthesitis, dactylitis, and axial disease
  • Characterization of how JAK inhibitors inhibit structural progression

Innovative Research in Inflammatory Conditions

Pfizer is also interested in supporting innovative research in other inflammatory conditions, some areas or examples include: Systemic Lupus Erythema, Vasculitis.